Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.
about
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
P2860
Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@en
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@nl
type
label
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@en
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@nl
prefLabel
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@en
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@nl
P2093
P2860
P356
P1476
Evaluation of primary androgen ...... using the J-CAPRA risk score.
@en
P2093
Hideyuki Akaza
Kazuhiro Suzuki
Masaru Murai
Michiyuki Usami
Mikio Namiki
Osamu Ogawa
Seiji Naito
Shiro Hinotsu
Tadaichi Kitamura
Taiji Tsukamoto
P2860
P356
10.12954/PI.12016
P577
2013-06-30T00:00:00Z